← 返回

FDA 批准的嵌合抗原受体(CAR)-T 细胞疗法用于不同癌症:近期视角

英文原题:FDA-Approved Chimeric Antigen Receptor (CAR)-T Cell Therapy for Different Cancers-A Recent Perspective.

查看英文原题

FDA-Approved Chimeric Antigen Receptor (CAR)-T Cell Therapy for Different Cancers-A Recent Perspective.

PubMed 2024/03/08(内容时间) Mol Biotechnol Q3 · IF 3.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

癌症是全球最常见的疾病之一,近几十年来发病率不断上升。本综述总结CAR-T(CAR-T)细胞疗法治疗多种癌症的新选择。癌症是重大健康与发展挑战,影响联合国可持续发展目标3所倡导的健康与福祉。世界卫生组织预计,到2030年,70%的癌症死亡将发生在中低收入国家(LMIC);LMIC还将承担预计每年新增2410万癌症病例的大部分负担。本综述聚焦CAR-T 细胞疗法治疗多种癌症,涵盖WHO和联合国可持续发展目标所关注的高发非传染性疾病癌症。研究者检索Google Scholar、ScienceDirect和PubMed三个文献数据库,收集2000年1月至2023年12月发表的不同癌症CAR-T 治疗研究。共找到18,700篇文章,其中48篇符合纳入标准,聚焦CAR-T 治疗多种癌症。根据收集的信息,本综述还讨论了CAR-T 治疗不同癌症的特点、优势及其改善部分癌症的能力,并详述相关分子机制。本文也探讨如何利用CAR-T 治疗方案帮助癌症患者摆脱严重疾病、延长生存,并在部分情况下实现疾病清除。

展开英文摘要原文

Cancer is one of the most prevalent diseases in the world, and their rate of occurence has been increased in recent decades. Current review article, summarizes the novel treatment options Chimeric Antigen Receptor-T (CAR-T) cell therapy for various cancers constitute a major health and development challenge, impacting every aspect of sustainable development quoted by goal 3 good health and well-being of UN sustainable goals. WHO estimates that 70% of cancer deaths occur in low- and middle- income countries (LMICs) by 2030, LMICs are expected to bear the brunt of the expected 24. 1 million new cancer cases per year. This current review article focuses and discussed about CAR-T cell therapy for various cancers against most prevalent non-communicable disease cancer disease stipulated by WHO and UN sustainable goals.

Three literature databases Google scholar, Science Direct, PubMed was utilized to search and collect CAR-T cell treatment options for different cancers published articles sources in between January 2000 and December 2023. There were a total of 18,700 papers found, with 48 of them being found to be eligible focusing various cancer treatment by CAR-T cells utilized for the study.

Based on the information gathered, CAR-T cell therapy treating different cancers and their merit and its advantages in heal and improve certain cancers was also discussed in this review article with their detailed molecular mechanisms. This article also gives an insight to utilize CAR-T cell treatment protocols for rejuvenating cancer patient from such ruthless cancer disease condition thereby improving life span of cancer patients and eradication of disease in some cases.

论文信息

作者
Thirumalaisamy R、Vasuki S、Sindhu SM、Mothilal TM、Srimathi V、Poornima B、Bhuvaneswari M、Hariharan M
单位
Department of Biotechnology, Sona College Arts and Science, Salem (Dt.), Tamil Nadu, 636005, India. tmalaisamy@gmail.com.India
文献类型
综述
期刊
Molecular biotechnology2025 Feb
原文标识
PubMed 38459361 · DOI 10.1007/s12033-024-01090-0